Tempus is making precision medicine a reality by applying AI in healthcare, deriving insights from our expansive library of clinical data and molecular data. We enable physicians to make real-time, data-driven decisions to deliver personalized care and targeted therapies for patients through our analytical machine learning platform that uses the power of artificial intelligence in healthcare. We also work with partners to facilitate discovery, development, and delivery of optimized therapeutic options for patients through distinctive solution sets. 

Our mission is for each patient to benefit from the treatment of others who came before by providing the healthcare industry tools that learn as we gather more data. It’s About Time. 

For more information, visit tempus.com and follow us on Twitter (@TempusLabs). 

Tempus AI

Our founder and CEO, Eric Lefkofky, joins mHUB for next week's HardTech Summit to discuss his path to #AI enabled healthcare. Register here: https://tempus.co/4c2W6Q2 

Dr. Ezra Cohen’s personal passion for taking care of cancer patients led him from decades of clinical care and research to Tempus as our Chief Medical Officer of Oncology. In our #TempusWhy series, Dr. Cohen shares how our work at Tempus fuels his unwavering commitment and determination to advancing cancer care. 

Hear more: 

Physicians like Dr. James and their care teams seamlessly use Tempus One to make informed patient treatment decisions through convenient functionalities that deliver insights on patient’s full clinical and molecular profile. By improving clinical workflows, One can allow more time for teams to focus on patient care. Learn more about Tempus One: https://tempus.co/42ZDYT4 

We’re looking forward to being on-site this week at the Liquid Biopsy for Precision Oncology Summit. Attend Adam Morabito’s presentation on how emerging technologies and multi-modal data have unlocked novel use cases for tumor-naïve liquid biopsies. Learn more: https://tempus.co/4bIlHha 

We’re #NowHiring for a Territory Sales Executive to join our team in North Atlanta. This position will drive new opportunities with major US cancer centers, clinics, and oncology practices. Join our growing sales team by applying here: https://bit.ly/3T6HkjX #atljobs 

Tempus COVID-19

TempusPRO for Patients

Tempus Provider

Tempus ONE

Domain Not Resolving

Google Tag Manager

Google Analytics

LetsEncrypt

DoubleClick.Net

Cloudflare CDN

Cloudflare Hosting

Person Schema

Cloudflare

Google

Owner

Alan Unger

Co-Owner

Arturo Orozco

Jim Rogers

Associate Director, Medical Tumor Board Liaison

Kristin Gunderson

Board and Development Assistant at Jewish Family Service of the Desert

Lee Brosnan

Chief Operating Officer

Ryan Fukushima

Shane Colley

Associate General Counsel

Tom Ferrone

Vice President Sales Central Region

Alana Bitikofer

Senior Vice President

Amy Franzen

David Agus

Steven Murray

Bradley Keywell

Eric Lefkofsky

Founder and CEO

Erik Phelps

Executive Vice President, Chief Administrative and Legal Officer

Lauren Silvis

Senior Vice President, External Affairs

Riccardo Miotto

Director of Machine Learning

David Landeck

Senior Director of Product

Nadav Weinberg

Head of Enterprise Infectious Disease Partnerships

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

Personalis is a contract research organization and genome-scale diagnostics services company specializing in genome guided medicine.

Artificial Intelligence (AI) Public Companies With More Than $10M in Revenue

Chicago Companies With More Than $1M in Revenue (Top 10K)

Investors Active in Oxfordshire

Greater Chicago Area Companies that Exited

Tempus is a technology company improving precision medicine through the practical application of artificial intelligence in healthcare. Their platform is designed to analyze and interpret clinical and molecular data to help healthcare providers deliver more personalized and effective treatments.

Debt Financing - Tempus

Venture Round - Tempus

Series G - Tempus

Baillie Gifford

Series F - Tempus

Series E - Tempus

T. Rowe Price

Series D - Tempus

New Enterprise Associates

Revolution

Series C - Tempus

Series B - Tempus

Computer and Software Services and Scientific Services

Chicago

Illinois

United States

North America

Tempus

Tempus to Report Third Quarter 2024 Financial Results on November 7

Avacta and Tempus Enter Strategic Collaboration to Advance AI-Driven Drug Development in Oncology

Tempus teams withTakeda to leverage multimodal real-world datasets in oncology

Longevity Startups Are Getting Funding, But Not As Fast As We’re Aging

Tempus AI, Inc.. (9/4/24). "Press Release: Tempus Announces Real World Data Collaboration with BioNTech". Chicago.

Tempus Announces Real World Data Collaboration with BioNTech

Tempus, BioNTech Ink Oncology Drug Discovery Research Collaboration

Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment

Personalis and Tempus Announce Expanded Collaboration

Spain

Europe

Pakistan

Asia

South Korea

Switzerland

HTML5

Adobe Flash

DigiCert

jQuery

Vimeo

Office 365

Amazon EC2

Bootstrap

COTA is a healthcare data analytics company that focuses on improving patient care and reducing costs through real-world evidence.

COTA

Fabric Genomics provides a comprehensive platform for genomic data analysis and interpretation, aiding in clinical decision-making and research.

Fabric Genomics

Flatiron Health is a healthcare technology company that focuses on organizing and leveraging real-world oncology data to improve cancer care.

Flatiron

Pentavere Research Group is a healthcare analytics company specializing in real-world evidence generation and analysis for pharmaceutical and healthcare organizations.

Pentavere Research Group

Genetron Health is a precision oncology company that provides comprehensive genomic profiling and molecular diagnostics for cancer patients.

Genetron Health

Holmusk is a digital health company that leverages real-world data and advanced analytics to provide insights for mental health and chronic disease management.

Holmusk

Tempus is a technology company that utilizes data and analytics to improve cancer care and research.

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 8, 2024 4:37 AM	69290919
news impact assignment basic	general	Mar 8, 2024 4:37 AM	aedd8d8d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 4:37 AM	0c195912
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Mar 8, 2024 4:37 AM	add56caf
news processing advanced	general
crunchbase trigger	general	Oct 31, 2024 9:55 AM	8e168438
crunchbase profile	general	Oct 31, 2024 10:12 AM	69efb5fc
li profile	general	Mar 8, 2024 4:37 AM	939ab9bb
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	90136484
peers	general	Mar 8, 2024 4:37 AM	24f90366
news basic	general	Mar 8, 2024 4:37 AM	b60e1978
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

TEM

COM:TEMPUS

Tempus

Last Close

56.79

08/11 21:00

Market Cap

5.77B

Beta: -

Volume Today

2.92M

Avg: -